Sirtris Pharmaceuticals, Inc.

Contact

Site Map

Sirtris is focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, such as Type 2 Diabetes. Our research focus is on modulating the sirtuins, a recently discovered class of enzymes involved in the aging process.

Sirtris, a GSK company www.gsk.com

+ 11.13.08	Nature Study Elucidates Mechanism of Calorie Restriction and Sirtuin Activation
+ 11.05.08	Research showing that Sirtris' SIRT1 activator NCE treats Diabetes in preclinical model published in Cell Metabolism
+ 10.17.08	Sirtris Presents at First Annual Boston Biotech R&D Conference
+ 10.16.08	Sirtris CEO Christoph Westphal Selected by Biotech CEOs as Outstanding Individual
+ 10.01.08	Sirtris’ Review of Sirtuin Therapeutics for Diseases of Aging in the Journal Nature Reviews Drug Discovery
+ 09.16.08	Sirtris Completes Exclusive License to Harvard's SIRT3-Based Intellectual Property
+ 09.05.08	Sirtris featured in conference call hosted by patient group MitoAction
+ 07.03.08	Long-Term Study of Middle-Aged Mice Shows Resveratrol Improves Health and Mimics Some Benefits of Dietary Restriction
+ 06.06.08	GlaxoSmithKline acquires Sirtris Pharmaceuticals, Inc., a world leader in sirtuin research and development

Find information regarding our clinical trials and areas of research. Learn more

+ 09.21.08

MitoAction Walk for Awareness 2008, Cambridge, MA (Sirtris Team)

This fall, Sirtris is looking to expand our dynamic team. If you’re looking for a fast-paced career in a creative and rewarding environment click here.